Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageDebt RatioDebt to EquityEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginGross MarginInterest Coverage RatioInventory AverageInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Invested CapitalReturn on SalesTimes Interest Earned

Journey Medical (DERM) Gross Margin (2020 - 2025)

Historic Gross Margin for Journey Medical (DERM) over the last 6 years, with Q3 2025 value amounting to 67.36%.

  • Journey Medical's Gross Margin fell 20800.0% to 67.36% in Q3 2025 from the same period last year, while for Sep 2025 it was 66.05%, marking a year-over-year decrease of 20100.0%. This contributed to the annual value of 62.81% for FY2024, which is 82800.0% down from last year.
  • Journey Medical's Gross Margin amounted to 67.36% in Q3 2025, which was down 20800.0% from 67.09% recorded in Q2 2025.
  • Journey Medical's Gross Margin's 5-year high stood at 85.27% during Q4 2023, with a 5-year trough of 43.05% in Q3 2021.
  • Over the past 5 years, Journey Medical's median Gross Margin value was 61.45% (recorded in 2024), while the average stood at 60.54%.
  • As far as peak fluctuations go, Journey Medical's Gross Margin tumbled by -231800bps in 2021, and later surged by 336100bps in 2023.
  • Journey Medical's Gross Margin (Quarter) stood at 45.62% in 2021, then increased by 13bps to 51.66% in 2022, then surged by 65bps to 85.27% in 2023, then dropped by -23bps to 65.64% in 2024, then increased by 3bps to 67.36% in 2025.
  • Its last three reported values are 67.36% in Q3 2025, 67.09% for Q2 2025, and 63.54% during Q1 2025.